Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.pdf
Resistance to TK inhibitors: KIT and PDGFRA Maria Debiec-Rychter, M.D., Ph.D. Center for Human Genetics, KULeuven, Belgium ESMO meeting Milan, May 13th,